TL;DR
Utah launched the first US pilot allowing AI to issue initial (not just refill) prescriptions without a doctor visit, starting October 5 with acne treatment via Nolla Health's app.
What happened
- Nolla Health's Nolla Derm app went live October 5 in Utah, issuing AI-generated initial acne prescriptions to adults 18 and older without a prior physician visit.
- The pilot was developed after months of coordination with the Utah Office of Artificial Intelligence Policy, making it the first of its kind in the US for new prescriptions.
- The app works via identity verification, a medical questionnaire, and a five-angle facial scan, generating a personalized treatment plan in 10 to 15 minutes.
- The AI selects only from a pre-approved, limited menu of acne treatments defined by physicians, not a free-form generative model.
- For the first 100 patients, every AI prescription requires independent sign-off from two licensed physicians before it reaches the patient.
Why it matters
- This crosses a line that prior AI health tools did not: issuing a new prescription, not just renewing one, which has historically required direct clinical judgment.
- Utah already faced physician backlash in April, when the Utah Medical Licensing Board urged suspension of the earlier Doctronic AI-renewal pilot, arguing it was live before regulators even knew it existed.
- The scale of unmet need is real: over 100,000 Utahns have acne, only 10 percent see a dermatologist, and average wait times run up to 61 days.
- Nolla Derm already has 175,000 downloads across 44 states, giving the company a ready distribution base if the pilot expands.
- A 95 percent physician-AI agreement threshold and zero serious adverse events are required before oversight loosens, setting a concrete benchmark other states could adopt or challenge.
What to watch next
- Whether the first 100-patient review clears the 95 percent agreement benchmark, which would trigger reduced physician oversight and signal the model is scalable.
- How the Utah Medical Licensing Board responds, given its prior move to suspend the Doctronic pilot and its stated concern that automated prescribing misses drug interactions and evolving symptoms.
- Whether other states adopt Utah's regulatory sandbox model, potentially opening AI prescribing to additional low-risk, protocol-driven conditions beyond acne.
Originally published on Present of AI, a daily source-linked AI news timeline. Read the full timeline or browse the open dataset.